title: Drug Screening in Neonates.
abstract: Gestational substance exposure continues to be a significant problem. Neonates may be exposed to various substances including illicit drugs, prescription drugs, and other legal substances that are best not used during pregnancy because of their potential deleterious effects as possible teratogens or their potential to create dependence and thus withdrawal in the neonate. Screening the newborn for gestational substance exposure is important for both acute care and early intervention to promote the best possible long-term outcomes. This column provides insight into what is known about the extent of substance use by pregnant women, an overview of neonatal biologic matrices for drug testing, and a discussion of the legal implications of neonatal substance screening.
authors.forename: Susan Givens
authors.initials: SG
authors.lastname: Bell
mesh_terms: D005260:Female; D006801:Humans; D007231:Infant, Newborn; D009357:Neonatal Abstinence Syndrome / Q000175:diagnosis* / Q000209:etiology; D015997:Neonatal Screening / Q000331:legislation & jurisprudence / Q000379:methods*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis*; D015813:Substance Abuse Detection / Q000331:legislation & jurisprudence / Q000379:methods*; D014481:United States